Michael J. Comb

Dr. Comb is a successful scientist and entrepreneur who founded Cell Signaling Technology, a company dedicated to the creation of research and diagnostic antibodies essential for cancer research. Michael envisioned a new antibody company, Bluefin Biomedicine, that leverages cutting edge technologies and expertise in antigen discovery, antibody technology and cancer biology to bring much needed antibody-based therapies to the cancer patient community. He started his career as Director of the Molecular Neurobiology Lab at Mass General Hospital and Associate Professor of Neuroscience at Harvard Medical School, Dr. Comb’s lab was interested in understanding the neural mechanisms underlying learning and memory. To address these biological questions, Dr. Comb recognized the need to assay intracellular signaling pathways and created the first phospho-specific antibodies (pAKT, pMAPK). Developing innovative technology to provide insight into disease mechanisms is Michael’s passion. At CST, Michael’s research efforts have focused on building antibody technologies and technologies to profile signaling pathways driving cancer. Dr. Comb has published over 60 peer-reviewed publications and is the inventor on numerous patents and patent applications. Dr. Comb holds a BS in Chemistry from the University of Massachusetts and a PhD in Chemistry from the University of Oregon.